Ligand Pharmaceuticals
LGND | NASDAQ
$301.71
-$7.08 (-2.29%)
At close: Nov 16, 2026, 4:00 PM ET
$300.00
-$1.71 (-0.57%)
After-hours:
Nov 16, 2026, 7:38 PM ET
Ligand Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Key Executives
| Name | Position |
|---|---|
| Todd C. Davis | Chief Executive Officer & Director |
| Andrew T. Reardon | Chief Legal Officer & Secretary |
| Octavio Espinoza | Chief Financial Officer |
| Karen R. Reeves | Senior Vice President of Investments & Head of Clinical Strategy |
| Keith Marschke | Senior Vice President of Biology & Scientific Affairs |
| Marjorie Fackovec | Head of People Operations |
| Melanie J. Herman | Executive Director of Investor Relations and Financial Planning & Analysis |
| Paul J. Hadden | Senior Vice President of Investments & Business Development |
| Richard Baxter | Senior VP of Investment Operations |
| Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 02, 2026 | 8-K/A | [Amend] Current Report |
| Aug 14, 2026 | 4 | Filing |
Ligand Pharmaceuticals
| Country | United States |
| IPO Date | Nov 18, 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Todd C. Davis |
Contact Details
555 Heritage Drive Jupiter,
Florida 33458 United States
Stock Details
| Ticker Symbol | LGND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886163 |
| CUSIP Number | 53220K504 |
| ISIN Number | US53220K5048 |
| SIC Code | 2834 |
Recent News
- 18 days ago / seekingalpha.comLigand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
- 19 days ago / marketbeat.comWhat Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
- 19 days ago / globenewswire.comLigand Reports Third Quarter 2026 Financial Results
- 20 days ago / globenewswire.comLigand to Participate in November Investor Conferences
- 1 month ago / globenewswire.comLigand to Report Third Quarter 2026 Financial Results on October 29, 2026
- 2 months ago / globenewswire.comLigand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
- 2 months ago / seekingalpha.comLigand Pharmaceuticals: Owning It Gives You A Stake Across Biotech
- 3 months ago / globenewswire.comLigand to Participate in September Investor Conferences
- 3 months ago / marketbeat.comLigand Pharmaceuticals Q2 Earnings Call Highlights
- 3 months ago / seekingalpha.comLigand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove LGND